Share Price and Basic Stock Data
Last Updated: November 7, 2025, 6:32 pm
| PEG Ratio | 0.67 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Bacil Pharma Ltd operates within the pharmaceuticals sector, characterized by a market capitalization of ₹57.8 Cr. The company’s current share price is ₹40.3, reflecting a price-to-earnings (P/E) ratio of 52.1. Notably, Bacil Pharma has reported no sales from June 2022 through September 2024, indicating a significant operational challenge. Despite the lack of revenue, the company has managed to generate some other income, peaking at ₹1.00 Cr in June 2025, which might suggest a shift in revenue strategies or asset utilization. The absence of sales raises concerns regarding the company’s market position and product pipeline. Furthermore, with a total of 7,532 shareholders and a public shareholding of 99.80%, investor interest appears robust despite the revenue stagnation. The company’s long-term viability hinges on its ability to address these revenue challenges and capitalize on any emerging opportunities within the sector.
Profitability and Efficiency Metrics
Bacil Pharma’s profitability metrics reveal a troubling trend, with a reported net profit of ₹1.11 Cr for the trailing twelve months (TTM). The company’s operating profit margins have consistently been negative, with a loss of ₹0.25 Cr reported for FY 2025, indicating persistent operational inefficiencies. The return on equity (ROE) stood at a mere 0.98%, while return on capital employed (ROCE) was slightly lower at 0.97%. These figures are substantially below industry averages, highlighting the company’s struggle to translate its capital into profitable operations. Moreover, the interest coverage ratio (ICR) remains unreported, suggesting potential liquidity issues. With expenses rising from ₹0.17 Cr in FY 2023 to ₹0.25 Cr in FY 2025, the company’s ability to manage costs effectively is critical for future profitability. The negative operating profit and lack of sales pose significant risks to Bacil Pharma’s operational sustainability.
Balance Sheet Strength and Financial Ratios
Bacil Pharma’s balance sheet reflects a cautious financial structure, characterized by total borrowings of just ₹0.16 Cr against reserves of ₹11.46 Cr as of FY 2025. This low level of debt gives the company a debt-to-equity ratio of 0.01, which is significantly lower than the typical industry range, indicating a conservative capital structure. The company’s book value per share has increased to ₹18.20, up from ₹1.86 in FY 2024, reflecting a positive change in net worth. However, the return on net worth is only 1.58%, which is below the sector standard, suggesting the need for improved asset utilization. Bacil Pharma’s current and quick ratios stand at 17.64, indicating strong liquidity. However, this high liquidity must be balanced with effective asset deployment to ensure long-term growth. The overall financial health, while stable from a liquidity perspective, requires strategic focus on enhancing profitability.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Bacil Pharma indicates a significant shift in ownership dynamics, with promoter holdings declining from 42.67% in September 2022 to just 0.20% by March 2025. This substantial decrease may raise concerns regarding management confidence and future strategic direction. In contrast, public ownership has surged from 57.33% to 99.80% during the same period, reflecting increased retail investor interest. This shift could signify a growing belief among the public in the company’s potential, despite its current operational challenges. The number of shareholders has also increased from 6,548 in September 2022 to 7,532 by June 2025, suggesting a broader acceptance and interest in Bacil Pharma’s shares. However, the declining promoter stake could be interpreted as a lack of confidence from the original owners, which may affect overall investor sentiment and future capital raising efforts.
Outlook, Risks, and Final Insight
Bacil Pharma faces a challenging landscape ahead, with its inability to generate revenue posing a significant risk to its sustainability. The company must swiftly address operational inefficiencies and explore avenues for revenue generation, possibly through new product development or strategic partnerships. Strengths such as a low debt level and a robust liquidity position provide a cushion against immediate financial distress. However, the declining promoter stake and stagnant sales growth could undermine investor confidence and future capital inflows. The path forward will require a strategic pivot to enhance operational effectiveness and reinvigorate sales. Should Bacil Pharma successfully navigate these challenges, it may leverage its strong liquidity to invest in growth initiatives. Conversely, failure to address the core issues could lead to further erosion of investor confidence and financial viability.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Bacil Pharma Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 138 Cr. | 110 | 247/84.3 | 31.5 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.52 Cr. | 1.84 | 4.33/1.82 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,949 Cr. | 454 | 479/192 | 111 | 22.8 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.1 Cr. | 46.0 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 37.0 Cr. | 25.3 | 29.1/17.0 | 38.6 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,891.31 Cr | 1,184.73 | 56.03 | 198.81 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Expenses | 0.05 | 0.04 | 0.04 | 0.09 | 0.03 | 0.04 | 0.05 | 0.06 | 0.04 | 0.07 | 0.06 | 0.07 | 0.11 |
| Operating Profit | -0.05 | -0.04 | -0.04 | -0.09 | -0.03 | -0.04 | -0.05 | -0.06 | -0.04 | -0.07 | -0.06 | -0.07 | -0.11 |
| OPM % | |||||||||||||
| Other Income | 0.07 | 0.04 | 0.00 | 0.01 | 0.05 | 0.03 | 0.03 | 0.02 | 0.01 | 0.56 | 0.00 | 0.09 | 1.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.02 | 0.00 | -0.04 | -0.08 | 0.02 | -0.01 | -0.02 | -0.04 | -0.03 | 0.49 | -0.06 | 0.02 | 0.89 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 24.72% | |
| Net Profit | 0.02 | 0.00 | -0.04 | -0.08 | 0.02 | -0.01 | -0.02 | -0.04 | -0.03 | 0.48 | -0.06 | 0.02 | 0.67 |
| EPS in Rs | 0.03 | 0.00 | -0.07 | -0.14 | 0.03 | -0.02 | -0.03 | -0.07 | -0.05 | 0.81 | -0.10 | 0.01 | 0.47 |
Last Updated: August 19, 2025, 10:45 pm
Below is a detailed analysis of the quarterly data for Bacil Pharma Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Expenses, as of Jun 2025, the value is 0.11 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.07 Cr. (Mar 2025) to 0.11 Cr., marking an increase of 0.04 Cr..
- For Operating Profit, as of Jun 2025, the value is -0.11 Cr.. The value appears to be declining and may need further review. It has decreased from -0.07 Cr. (Mar 2025) to -0.11 Cr., marking a decrease of 0.04 Cr..
- For OPM %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Other Income, as of Jun 2025, the value is 1.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.09 Cr. (Mar 2025) to 1.00 Cr., marking an increase of 0.91 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.89 Cr.. The value appears strong and on an upward trend. It has increased from 0.02 Cr. (Mar 2025) to 0.89 Cr., marking an increase of 0.87 Cr..
- For Tax %, as of Jun 2025, the value is 24.72%. The value appears to be increasing, which may not be favorable. It has increased from 0.00% (Mar 2025) to 24.72%, marking an increase of 24.72%.
- For Net Profit, as of Jun 2025, the value is 0.67 Cr.. The value appears strong and on an upward trend. It has increased from 0.02 Cr. (Mar 2025) to 0.67 Cr., marking an increase of 0.65 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.47. The value appears strong and on an upward trend. It has increased from 0.01 (Mar 2025) to 0.47, marking an increase of 0.46.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:50 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Expenses | 0.09 | 0.11 | 0.13 | 0.17 | 0.29 | 0.26 | 0.18 | 0.16 | 0.16 | 0.17 | 0.19 | 0.25 | 0.31 |
| Operating Profit | -0.09 | -0.11 | -0.13 | -0.17 | -0.29 | -0.26 | -0.18 | -0.16 | -0.16 | -0.17 | -0.19 | -0.25 | -0.31 |
| OPM % | |||||||||||||
| Other Income | -0.01 | 0.08 | 0.06 | 0.17 | -3.42 | -0.07 | -0.12 | -0.07 | -3.70 | 0.07 | 0.13 | 0.66 | 1.65 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.11 | -0.03 | -0.07 | 0.00 | -3.75 | -0.34 | -0.32 | -0.23 | -3.86 | -0.10 | -0.06 | 0.41 | 1.34 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||
| Net Profit | -0.11 | -0.03 | -0.07 | 0.00 | -3.75 | -0.34 | -0.32 | -0.24 | -3.86 | -0.10 | -0.06 | 0.40 | 1.11 |
| EPS in Rs | -0.19 | -0.05 | -0.12 | 0.00 | -6.37 | -0.58 | -0.54 | -0.41 | -6.55 | -0.17 | -0.10 | 0.28 | 1.19 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 72.73% | -133.33% | 100.00% | 90.93% | 5.88% | 25.00% | -1508.33% | 97.41% | 40.00% | 766.67% |
| Change in YoY Net Profit Growth (%) | 0.00% | -206.06% | 233.33% | -9.07% | -85.05% | 19.12% | -1533.33% | 1605.74% | -57.41% | 726.67% |
Bacil Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 31% |
| 5 Years: | 54% |
| 3 Years: | 82% |
| TTM: | 1210% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 64% |
| 3 Years: | 102% |
| 1 Year: | 69% |
| Return on Equity | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | -1% |
| 3 Years: | 1% |
| Last Year: | 3% |
Last Updated: September 5, 2025, 2:31 pm
No data available for the Balance Sheet data table.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -0.17 | -0.25 | -0.40 | -0.48 | -0.29 | -0.36 | -0.35 | -0.34 | -0.19 | -0.19 | -0.29 | -0.41 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | ||||||||||||
| Inventory Days | ||||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | ||||||||||||
| Working Capital Days | ||||||||||||
| ROCE % | -0.61% | -0.45% | -1.05% | -1.49% | -6.01% | -8.47% | -2.80% | -5.75% | -7.07% | -12.61% | -13.11% | -0.97% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.64 | -0.10 | -0.17 | -6.55 | -0.41 |
| Diluted EPS (Rs.) | 0.64 | -0.10 | -0.17 | -6.55 | -0.41 |
| Cash EPS (Rs.) | 0.28 | -0.08 | -0.15 | -5.91 | -0.35 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 18.20 | 1.86 | 1.68 | 1.88 | 2.13 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 18.20 | 1.86 | 1.68 | 1.88 | 2.13 |
| PBDIT / Share (Rs.) | 0.29 | -0.08 | -0.15 | -5.91 | -0.35 |
| PBIT / Share (Rs.) | 0.29 | -0.09 | -0.15 | -5.91 | -0.36 |
| PBT / Share (Rs.) | 0.29 | -0.09 | -0.15 | -5.91 | -0.36 |
| Net Profit / Share (Rs.) | 0.28 | -0.09 | -0.15 | -5.91 | -0.36 |
| Return on Networth / Equity (%) | 1.58 | -4.85 | -9.26 | -315.24 | -17.19 |
| Return on Capital Employeed (%) | 1.60 | -4.86 | -9.26 | -315.26 | -17.22 |
| Return On Assets (%) | 1.57 | -4.44 | -9.03 | -303.54 | -5.85 |
| Total Debt / Equity (X) | 0.01 | 0.08 | 0.01 | 0.02 | 0.12 |
| Current Ratio (X) | 17.64 | 0.46 | 8.19 | 10.63 | 1.04 |
| Quick Ratio (X) | 17.64 | 0.46 | 8.19 | 10.63 | 1.04 |
| Enterprise Value (Cr.) | 22.33 | 9.61 | 3.57 | 3.54 | 2.11 |
| EV / EBITDA (X) | 138.79 | -168.53 | -35.97 | -0.91 | -9.00 |
| Price / BV (X) | 2.33 | 7.87 | 3.25 | 3.06 | 1.46 |
| EarningsYield | 0.01 | -0.01 | -0.02 | -1.03 | -0.11 |
After reviewing the key financial ratios for Bacil Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.64. This value is below the healthy minimum of 5. It has increased from -0.10 (Mar 24) to 0.64, marking an increase of 0.74.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.64. This value is below the healthy minimum of 5. It has increased from -0.10 (Mar 24) to 0.64, marking an increase of 0.74.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.28. This value is below the healthy minimum of 3. It has increased from -0.08 (Mar 24) to 0.28, marking an increase of 0.36.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 18.20. It has increased from 1.86 (Mar 24) to 18.20, marking an increase of 16.34.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 18.20. It has increased from 1.86 (Mar 24) to 18.20, marking an increase of 16.34.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.29. This value is below the healthy minimum of 2. It has increased from -0.08 (Mar 24) to 0.29, marking an increase of 0.37.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.29. This value is within the healthy range. It has increased from -0.09 (Mar 24) to 0.29, marking an increase of 0.38.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.29. This value is within the healthy range. It has increased from -0.09 (Mar 24) to 0.29, marking an increase of 0.38.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.28. This value is below the healthy minimum of 2. It has increased from -0.09 (Mar 24) to 0.28, marking an increase of 0.37.
- For Return on Networth / Equity (%), as of Mar 25, the value is 1.58. This value is below the healthy minimum of 15. It has increased from -4.85 (Mar 24) to 1.58, marking an increase of 6.43.
- For Return on Capital Employeed (%), as of Mar 25, the value is 1.60. This value is below the healthy minimum of 10. It has increased from -4.86 (Mar 24) to 1.60, marking an increase of 6.46.
- For Return On Assets (%), as of Mar 25, the value is 1.57. This value is below the healthy minimum of 5. It has increased from -4.44 (Mar 24) to 1.57, marking an increase of 6.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.01. This value is within the healthy range. It has decreased from 0.08 (Mar 24) to 0.01, marking a decrease of 0.07.
- For Current Ratio (X), as of Mar 25, the value is 17.64. This value exceeds the healthy maximum of 3. It has increased from 0.46 (Mar 24) to 17.64, marking an increase of 17.18.
- For Quick Ratio (X), as of Mar 25, the value is 17.64. This value exceeds the healthy maximum of 2. It has increased from 0.46 (Mar 24) to 17.64, marking an increase of 17.18.
- For Enterprise Value (Cr.), as of Mar 25, the value is 22.33. It has increased from 9.61 (Mar 24) to 22.33, marking an increase of 12.72.
- For EV / EBITDA (X), as of Mar 25, the value is 138.79. This value exceeds the healthy maximum of 15. It has increased from -168.53 (Mar 24) to 138.79, marking an increase of 307.32.
- For Price / BV (X), as of Mar 25, the value is 2.33. This value is within the healthy range. It has decreased from 7.87 (Mar 24) to 2.33, marking a decrease of 5.54.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has increased from -0.01 (Mar 24) to 0.01, marking an increase of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Bacil Pharma Ltd:
- Net Profit Margin: 0%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 1.6% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 1.58% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 17.64
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 36.4 (Industry average Stock P/E: 56.03)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.01
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | G2/G3, Samarpan Complex, Next To Mirador Hotel, Link Road, Mumbai Maharashtra 400099 | bacilpha@yahoo.com https://bacilpharma.co.in |
| Management | |
|---|---|
| Name | Position Held |
| Ms. Chaitali Kalpataru Shah | Executive Director & CFO |
| Mr. Dinesh Chander Notiyal | Independent Director |
| Ms. Avani Savjibibhai Godhaniya | Independent Director |